Literature DB >> 21090615

Conformational remodeling of femtomolar inhibitor-acetylcholinesterase complexes in the crystalline state.

Yves Bourne1, Zoran Radić, Palmer Taylor, Pascale Marchot.   

Abstract

The active center of acetylcholinesterase (AChE), a target site for competitive inhibitors, resides centrosymmetric to the subunit at the base of a deep, narrow gorge lined by aromatic residues. At the gorge entry, a peripheral site encompasses overlapping binding loci for noncompetitive inhibitors, which alter substrate access to the gorge. The click-chemistry inhibitor TZ2PA6 links the active center ligand, tacrine, to the peripheral site ligand, propidium, through a biorthogonal reaction of an acetylene and an azide that forms either a syn1 or an anti1 triazole. Compared with wild-type mouse AChE, a Tyr337Ala mutant displays full catalytic activity, albeit with 2-3 orders of magnitude higher affinities for the TZ2PA6 syn1 and anti1 regioisomers, reflected in low femtomolar K(d) values, diffusion-limited association, and dissociation half-times greater than 1 month and 1 week, respectively. Three structures of each of the co-crystallized syn1 and anti1 complexes of the Tyr337Ala mutant were solved at three distinct times of crystal maturation, consistent with or exceeding the half-lives of the complexes in solution, while crystalline complexes obtained from soaked Tyr337Ala crystals led to picturing "freshly formed" complexes. The structures, at 2.55-2.75 Å resolution, reveal a range of unprecedented conformations of the bound regioisomers, not observed in the wild-type AChE complexes, associated with concerted positional rearrangements of side chains in the enzyme gorge. Moreover, time-dependent conformational remodeling of the crystalline complexes appears to correlate with the dissociation half-times of the solution complexes. Hence, for the tight-binding TZ2PA6 inhibitors, the initial complexes kinetically driven in solution slowly form more stable complexes governed by thermodynamic equilibrium and observable in mature crystals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21090615      PMCID: PMC3016896          DOI: 10.1021/ja106820e

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  35 in total

1.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.

Authors:  G Kryger; I Silman; J L Sussman
Journal:  Structure       Date:  1999-03-15       Impact factor: 5.006

2.  The maximal affinity of ligands.

Authors:  I D Kuntz; K Chen; K A Sharp; P A Kollman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

3.  Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site.

Authors:  Yves Bourne; Palmer Taylor; Zoran Radić; Pascale Marchot
Journal:  EMBO J       Date:  2003-01-02       Impact factor: 11.598

4.  A new and rapid colorimetric determination of acetylcholinesterase activity.

Authors:  G L ELLMAN; K D COURTNEY; V ANDRES; R M FEATHER-STONE
Journal:  Biochem Pharmacol       Date:  1961-07       Impact factor: 5.858

5.  Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks.

Authors:  Warren G Lewis; Luke G Green; Flavio Grynszpan; Zoran Radić; Paul R Carlier; Palmer Taylor; M G Finn; K Barry Sharpless
Journal:  Angew Chem Int Ed Engl       Date:  2002-03-15       Impact factor: 15.336

6.  Curariform antagonists bind in different orientations to acetylcholine-binding protein.

Authors:  Fan Gao; Nina Bern; Alicia Little; Hai-Long Wang; Scott B Hansen; Todd T Talley; Palmer Taylor; Steven M Sine
Journal:  J Biol Chem       Date:  2003-04-07       Impact factor: 5.157

7.  Curariform antagonists bind in different orientations to the nicotinic receptor ligand binding domain.

Authors:  Hai-Long Wang; Fan Gao; Nina Bren; Steven M Sine
Journal:  J Biol Chem       Date:  2003-06-10       Impact factor: 5.157

8.  Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding.

Authors:  P Taylor; S Lappi
Journal:  Biochemistry       Date:  1975-05-06       Impact factor: 3.162

Review 9.  The growing impact of click chemistry on drug discovery.

Authors:  Hartmuth C Kolb; K Barry Sharpless
Journal:  Drug Discov Today       Date:  2003-12-15       Impact factor: 7.851

10.  Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation.

Authors:  Yves Bourne; Hartmuth C Kolb; Zoran Radić; K Barry Sharpless; Palmer Taylor; Pascale Marchot
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-02       Impact factor: 11.205

View more
  10 in total

1.  Generation of candidate ligands for nicotinic acetylcholine receptors via in situ click chemistry with a soluble acetylcholine binding protein template.

Authors:  Neil P Grimster; Bernhard Stump; Joseph R Fotsing; Timo Weide; Todd T Talley; John G Yamauchi; Ákos Nemecz; Choel Kim; Kwok-Yiu Ho; K Barry Sharpless; Palmer Taylor; Valery V Fokin
Journal:  J Am Chem Soc       Date:  2012-04-06       Impact factor: 15.419

2.  Neurotoxicology of bis(n)-tacrines on Blattella germanica and Drosophila melanogaster acetylcholinesterase.

Authors:  James M Mutunga; Dhana Raj Boina; Troy D Anderson; Jeffrey R Bloomquist; Paul R Carlier; Dawn M Wong; Polo C-H Lam; Maxim M Totrov
Journal:  Arch Insect Biochem Physiol       Date:  2013-06-05       Impact factor: 1.698

3.  Synthesis of selective agonists for the α7 nicotinic acetylcholine receptor with in situ click-chemistry on acetylcholine-binding protein templates.

Authors:  John G Yamauchi; Kimberly Gomez; Neil Grimster; Mikael Dufouil; Akos Nemecz; Joseph R Fotsing; Kwok-Yiu Ho; Todd T Talley; K Barry Sharpless; Valery V Fokin; Palmer Taylor
Journal:  Mol Pharmacol       Date:  2012-07-11       Impact factor: 4.436

4.  A New Class of Bi- and Trifunctional Sugar Oximes as Antidotes against Organophosphorus Poisoning.

Authors:  Ophélie Da Silva; Nicolas Probst; Christophe Landry; Anne-Sophie Hanak; Pierre Warnault; Caroline Coisne; André-Guilhem Calas; Fabien Gosselet; Charlotte Courageux; Anne-Julie Gastellier; Marilène Trancart; Rachid Baati; Marie-Pierre Dehouck; Ludovic Jean; Florian Nachon; Pierre-Yves Renard; José Dias
Journal:  J Med Chem       Date:  2022-03-07       Impact factor: 7.446

5.  Automated docking with protein flexibility in the design of femtomolar "click chemistry" inhibitors of acetylcholinesterase.

Authors:  Garrett M Morris; Luke G Green; Zoran Radić; Palmer Taylor; K Barry Sharpless; Arthur J Olson; Flavio Grynszpan
Journal:  J Chem Inf Model       Date:  2013-03-29       Impact factor: 4.956

6.  The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex.

Authors:  Orly Dym; Wanling Song; Clifford Felder; Esther Roth; Valery Shnyrov; Yacov Ashani; Yechun Xu; Robbie P Joosten; Lev Weiner; Joel L Sussman; Israel Silman
Journal:  Protein Sci       Date:  2016-03-28       Impact factor: 6.725

7.  Acetylcholinesterase inhibitors with photoswitchable inhibition of β-amyloid aggregation.

Authors:  Xinyu Chen; Sarah Wehle; Natascha Kuzmanovic; Benjamin Merget; Ulrike Holzgrabe; Burkhard König; Christoph A Sotriffer; Michael Decker
Journal:  ACS Chem Neurosci       Date:  2014-03-14       Impact factor: 4.418

Review 8.  Tailored therapeutics based on 1,2,3-1H-triazoles: a mini review.

Authors:  Parteek Prasher; Mousmee Sharma
Journal:  Medchemcomm       Date:  2019-05-14       Impact factor: 3.597

9.  Expanding the palette of phenanthridinium cations.

Authors:  Andrew G Cairns; Hans Martin Senn; Michael P Murphy; Richard C Hartley
Journal:  Chemistry       Date:  2014-03-24       Impact factor: 5.236

10.  Use of connectivity index and simple topological parameters for estimating the inhibition potency of acetylcholinesterase.

Authors:  Ante Miličević; Goran Šinko
Journal:  Saudi Pharm J       Date:  2022-02-08       Impact factor: 4.562

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.